Evidence map›Paper›PMID 24139680›Full record

ArticleThe Lancet. Neurology2013

Advancing care for traumatic brain injury: findings from the IMPACT studies and perspectives on future research.

Andrew I R Maas, Gordon D Murray, Bob Roozenbeek, Hester F Lingsma, Isabella Butcher, Gillian S McHugh, James Weir, Juan Lu, Ewout W Steyerberg, International Mission on Prognosis Analysis of Clinical Trials in Traumatic Brain Injury (IMPACT) Study Group

Abstract read
In one paragraph

Article in The Lancet. Neurology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed, 3 pooled it
10.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

66 citing papers in PubMed, 3 syntheses or guidelines pooled it, 169 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Trial
  5. Efficacy and safety of cerebrolysin in neurorecovery after moderate-severe traumatic brain injury: results from the CAPTAIN II trial.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2020
    Trial
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. PredictiveACS omega · 2026
    Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Observational
  17. Observational
  18. ApoE Mimetic Peptides as Therapy for Traumatic Brain Injury.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2023
    Review
  19. Article
  20. Review

6 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 4 countries.

Andrew I R MaasDepartment of Neurosurgery, Antwerp University Hospital and University of Antwerp, Edegem, Belgium. Electronic address: andrew.maas@uza.be.
Gordon D Murray
Bob Roozenbeek
Hester F Lingsma
Isabella Butcher
Gillian S McHugh
James Weir
Juan Lu
Ewout W Steyerberg
International Mission on Prognosis Analysis of Clinical Trials in Traumatic Brain Injury (IMPACT) Study Group
University of Edinburgh · GBErasmus MC · NLAntwerp University Hospital · BEVirginia Commonwealth University · US

Funding

Clinical trial design and analysis in traumatic brain injuryR01NS042691 · NINDS · UNIVERSITY HOSPITAL ANTWERP · PI MAAS, ANDREW · 2003 to 2009
$2.9M
Medical Research Council G0800803NINDS NIH HHS NS-042691NINDS NIH HHS R01 NS042691
6 · The paper itself

Abstract

Research in traumatic brain injury (TBI) is challenging for several reasons; in particular, the heterogeneity between patients regarding causes, pathophysiology, treatment, and outcome. Advances in basic science have failed to translate into successful clinical treatments, and the evidence underpinning guideline recommendations is weak. Because clinical research has been hampered by non-standardised data collection, restricted multidisciplinary collaboration, and the lack of sensitivity of classification and efficacy analyses, multidisciplinary collaborations are now being fostered. Approaches to deal with heterogeneity have been developed by the IMPACT study group. These approaches can increase statistical power in clinical trials by up to 50% and are also relevant to other heterogeneous neurological diseases, such as stroke and subarachnoid haemorrhage. Rather than trying to limit heterogeneity, we might also be able to exploit it by analysing differences in treatment and outcome between countries and centres in comparative effectiveness research. This approach has great potential to advance care in patients with TBI.

Indexed as

AdultBlood PressureBrain InjuriesCanadaData CollectionDisease ManagementEuropeForecastingGlasgow Coma ScaleHumansInternational CooperationMiddle AgedModels, NeurologicalMulticenter Studies as TopicNational Institute of Neurological Disorders and Stroke (U.S.)National Institutes of Health (U.S.)

Identifiers

PMID24139680
PMCPMC3895622
OpenAlexW2105035887

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.